About Gossamer Bio
Gossamer Bio is a company based in San Diego (United States) founded in 2017 by Faheem Hasnain. Gossamer Bio has raised $330 million across 4 funding rounds from investors including Arch Venture Partners, Monashee Investment Management and EcoR1. The company has 145 employees as of December 31, 2024. Gossamer Bio has completed 1 acquisition, including Respira Therapeutics. Gossamer Bio offers products and services including Seralutinib. Gossamer Bio operates in a competitive market with competitors including Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.
- Headquarter San Diego, United States
- Employees 145 as on 31 Dec, 2024
- Founders Faheem Hasnain
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Gossamer Bio, Inc.
-
Annual Revenue
$114.7 M (USD)0as on Dec 31, 2024
-
Net Profit
-$56.53 M (USD)68.56as on Dec 31, 2024
-
EBITDA
-$55.77 M (USD)67.07as on Dec 31, 2024
-
Total Equity Funding
$330 M (USD)
in 4 rounds
-
Latest Funding Round
$212.1 M (USD), Post-IPO
Jul 20, 2023
-
Investors
Arch Venture Partners
& 11 more
-
Employee Count
145
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Gossamer Bio
Gossamer Bio is a publicly listed company on the NASDAQ with ticker symbol GOSS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Gossamer Bio
Gossamer Bio offers a comprehensive portfolio of products and services, including Seralutinib.
Inhaled inhibitor for treating pulmonary hypertension diseases.
People of Gossamer Bio
Unlock access to complete
Unlock access to complete
Funding Insights of Gossamer Bio
Gossamer Bio has successfully raised a total of $330M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $212.1 million completed in July 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Gossamer Bio
Gossamer Bio has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Arch Venture Partners, Monashee Investment Management and EcoR1.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked | |
|
Early-stage and late-stage biotech and finance companies are funded.
|
Locked | Locked | Locked | |
|
Long-term private equity investments in transformational opportunities are pursued.
|
Locked | Locked | Locked |
Investor details for Gossamer Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Gossamer Bio
Gossamer Bio has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Respira Therapeutics.
Investment portfolio details for Gossamer Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapeutics to treat Pulmonary Arterial Hypertension using proprietary drug delivery technology.
|
Locked | Locked | 2010 | Locked |
Complete acquisition details for Gossamer Bio
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Gossamer Bio
Detailed financials for Gossamer Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Gossamer Bio Comparisons
Peer comparison for Gossamer Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Gossamer Bio
Gossamer Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| Locked | Locked | Locked |
GPCR drug discovery platform is developed for multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for allergic and inflammatory diseases are developed.
|
Detailed competitors of Gossamer Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Gossamer Bio
Complete news archive for Gossamer Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gossamer Bio
Gossamer Bio was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Gossamer Bio is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Faheem Hasnain is the current CEO of Gossamer Bio. They have also founded this company.
Gossamer Bio is a funded company, having raised a total of $330M across 4 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Gossamer Bio is 145.
Annual revenue of Gossamer Bio is $114.7M as on Dec 31, 2024.
Gossamer Bio was founded in 2017 and is headquartered in San Diego, United States. Operations focus on the biotechnology sector, where small molecule-based therapies are developed to address immunological disorders, inflammation, and cancer. Drug candidates include GB001, targeted at inflammatory disorders with an undisclosed mechanism, and first-in-class HIF-1α stabilizers designed for inflammatory bowel diseases.
Gossamer Bio's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.
Gossamer Bio offers Seralutinib.
Yes, Gossamer Bio is publicly traded on NASDAQ under the ticker symbol GOSS.
Gossamer Bio has made 1 acquisition, including Respira Therapeutics.
Gossamer Bio has 12 investors. Key investors include Arch Venture Partners, Monashee Investment Management, EcoR1, NEA, and Weiss Asset Management.
The ticker symbol of Gossamer Bio is GOSS on NASDAQ.